MaxCyte signed a strategic platform license (SPL) with Walking Fish Therapeutics which focuses on B cell-based therapeutics. Walking Fish obtains non-exclusive clinical and commercial rights to use ...
The disclosed investors in the Series A round of financing are Emerson Collective, Illumina Ventures, and Quan Capital. B cells are a type of white blood cell that produces antibodies. Walking Fish is ...
Hoping to evolve new treatments across the board using B-cell therapies, Walking Fish Therapeutics has nabbed $50 million and a new chief in the form of an industry veteran. It’s been four years since ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Walking Fish Therapeutics, a leader in B cell engineering, today announced it has appointed Georgia Erbez as Chief Operating Officer and moved to a new 22 ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Walking Fish Therapeutics, a leader in B cell therapeutics, today announced the completion of an oversubscribed Series A financing, raising a total of $73 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results